Potential Antiviral Effect of Chloroquine Therapy against SARS-CoV-2 Infection by Musa, Imad R.
184 https://www.id-press.eu/mjms/index
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Sep 20; 8(T1):184-192.
https://doi.org/10.3889/oamjms.2020.4854
eISSN: 1857-9655
Category: T1 - Thematic Issue “Coronavirus Disease (COVID-19)”
Section: Systematic Review Article
Potential Antiviral Effect of Chloroquine Therapy against 
SARS-CoV-2 Infection
Imad R. Musa*
Department of Internal Medicine, Royal Commission Hospital, Jubail, Saudi Arabia
Abstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has affected many countries with increasing 
morbidity and mortality. In the absence of an effective vaccine and medication, chloroquine may be a potential choice.
AIM: This study aims to explore the role of the possible antiviral effects of chloroquine against SARS-CoV-2.
MATERIALS AND METHODS: A systematic search of studies relating to the antiviral effects against coronaviruses 
was conducted between January 1, 1990, and up to May 26, 2020, for relevant studies using PubMed, Scopus, and 
Google Scholar.
RESULTS: A total of 174 articles were initially identified. Ninety-seven papers were removed for failing to address the 
aim of the study. Seventy-seven full-text articles were retrieved for eligibility analysis. Ten studies focused on general 
inhibition of viral replication, ten evaluated its effects on angiotensin-converting enzyme 2, 19 addressed the effects 
on alkalizing the cellular pH, 25 concentrated on the immunomodulatory effect, two assessed the potential effects on 
sialic acid, and 24 explored the therapeutic outcome.
CONCLUSION: Chloroquine has promising antiviral effects on SARS-CoV-2 at different levels.
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Introduction
In December 2019, a cluster of reported chest 
infections among citizens in Wuhan, China, that were 
caused by a newly isolated β-coronavirus, which was 
initially named “2019 Novel Coronavirus” (2019-nCoV) 
on January 12, 2020, by the World Health Organization 
(WHO). While the WHO officially named the disease 
coronavirus disease 2019 (COVID-19) on February 11, 
2020, the International Committee Coronavirus Study 
Group suggested naming it “Severe Acute Respiratory 
Syndrome Coronavirus 2” (SARS-CoV-2) on the same 
day [1]. Human-to-human transmission of SARS-
CoV-2 was observed mainly in close direct contact, a 
recent history of travel to Wuhan (72.3%) and among 
healthcare workers (3.8%) [2]. In contrast to COVID-19, 
SARS infection was relatively high among healthcare 
workers (33–42%), and almost similar contact rate (62–
79%) [3], [4]. On March 12, 2020, the WHO declared 
COVID-19 to be a global pandemic and Italy was 
identified as the second most affected country with a 
higher case fatality rate (CFR) [5]. A week later, over 
100 countries reported positive cases of COVID-19 with 
increased morbidities and mortalities [6]. Surprisingly, a 
recent time-delay adjusted estimation indicates that the 
COVID-19 CFR reached 20% in Wuhan compared to 
the cumulative number of deaths (5.6%) [7]. The rapid 
spread of the disease to the pandemic level, higher rate 
of morbidity and mortality, exhaustion of health facilities 
in the affected countries, non-availability of a vaccine, 
non-availability of approved medications for COVID-19, 
and previous reports of antiviral effects of chloroquine 
suggest chloroquine as a potential treatment option to 
modify the nature of the disease. The in vitro antiviral 
activity of chloroquine was observed in the late 1960s [8]. 
Recently, there has been a growing body of evidence 
during the COVID-19 pandemic that shows the antiviral 
efficacy of hydroxychloroquine alone or in combination 
with other medications [1], [9], [10], [11], [12].
The anti-inflammatory and immunomodulatory 
actions of chloroquine analogs have been 
reported in the treatment of viral infections and 
their pathologies [13]. Both chloroquine and 
hydroxychloroquine can negatively affect the 
growth of many different members of human 
coronavirus [14], [15]. Recently, a higher efficacy 
was reported in an in vitro study, favoring the control 
of SARS-CoV-2 infection [16]. Chloroquine analog in 
combination with other antiviral drugs is considered an 
effective option for therapy for viral diseases to avoid the 
interaction of P-glycoprotein and multidrug-resistance 
associated proteins in these viruses, which extrude 
medications from the cells and cellular organelles [17]. 
The results of chloroquine use in various in vitro 
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studies demonstrated its effect on cellular pH [18], 
and it inhibits replication of several DNA and RNA 
viruses [19] and interferes with terminal glycosylation 
of the cellular receptor angiotensin-converting enzyme 
2 (ACE2) [20]. Hence, chloroquine was recently used 
in the management of COVID-19 during the current 
pandemic outbreak [1], [9], [10], [11], [12]. Chloroquine 
has long been used as an antimalarial and anti-
inflammatory agent. It has a reasonable degree of 
safety at a low price. For these reasons, we decided 
to conduct this study to explore the possible antiviral 
effects of chloroquine and the possible mechanism of 
action to improve our understanding of this drug and 
shed light on it for potential future studies.
Materials and Methods
A systematic search of studies relating to 
chloroquine’s antiviral effect against coronavirus 
was performed between January 01, 1990 and up to 
May 26, 2020 using PubMed, Scopus, and Google 
Scholar. We used combinations of the following search 
terms: “Chloroquine,” “hydroxychloroquine,” “antiviral 
action,” “mechanism” safety” efficacy” “COVID-19,” 
and “SARS-CoV-2.” The preferred reporting items for 
systematic review and meta-analysis guidelines were 
adopted, as illustrated in Figure 1 [21]. The electronic 
database search yielded 174 articles. Ninety-seven 
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Figure 1: Flow chart of the study selection
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studies were removed for not addressing the aim of the 
study, duplication, lacking a proper citation, and not being 
within the period decided beforehand. Titles and abstracts 
were assessed to identify eligibility for full screening. 
Studies that employed acceptable quantitative and/or 
qualitative methods, including randomized controlled 
trials, observational studies (such as cross-sectional, 
experimental, and interventional studies), review articles, 
ideas, editorials, letters to the editor, and opinions were 
included in the study. All articles focusing on the potential 
possible antiviral effects of chloroquine, the mechanism 
of action and therapeutic outcomes were eligible for 
inclusion. Then, all relevant studies were selected and 
full-text manuscripts retrieved for assessment. The clinical 
opinions were critically appraised using the recommended 
checklist by McArthur et al. (2015) to focus on relevant 
articles [22]. The studies were grouped according to 
the primary aims, focusing on viral replication inhibition, 
chloroquine’s action on ACE2, alkalization at the cellular 
level, chloroquine immunomodulatory effects, effects on 
sialic acid, therapeutic trials and studies that addressed 
more than one item. This enabled grouping of articles that 
focused specific targets and issues relevant to the study 
objectives and facilitated the retrieval of information.
Results
A total of 174 articles were initially identified. 
Ninety-seven studies were removed for not addressing 
the aim of the study, duplication, lack of proper 
citations, and poor use of language. After screening 
titles and abstracts, 77 full-text articles were retrieved 
for eligibility analysis. Ten studies focused on general 
viral replication inhibition [14], [19], [20], [21], [22], 
[23], [24], [25], [26], [27], ten evaluated its effects on 
ACE2 [13], [15], [28], [29], [30], [31], [32], [33], [34], 19 
addressed the effects on alkalizing the cellular pH [13], 
[15], [31], [32], [33], [35], [36], [37], [38], [39], [40], [41], 
[42], [43], [44], [45], [46], [47], [48], 25 concentrated on 
chloroquine therapy as an immunomodulator [13], [16], 
[26], [37], [49], [50], [51], [52], [53], [54], [55], [56], [57], 
[58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], 
[69], two assessed the potential effects on sialic acid 
[70], [71], 24 articles explored the therapeutic outcome 
[1], [5], [15], [16], [20], [35], [68], [69], [72], [73], [74], 
[75], [76], [77], [78], [80], [81], [82], [83], [84], [85], and 
nine addressed more than one target [13], [15], [16], 
[26], [31], [32], [35], [33], [37].
Discussion
The review of articles indicates that chloroquine 
has broad-spectrum antiviral activities at different 
sites and levels. These properties have caused many 
researchers to conduct studies and explore their 
potential effects. Some studies have focused on the 
general inhibition of viral cycle replication without 
illustrating details. Chloroquine, widely promoted as 
an antimalarial and autoimmune disease drug, was 
recently shown to have a potential broad-spectrum 
antiviral effect that interferes with the viral replication 
cycle [23], [24]. This was supported by the outcome of 
many in vitro studies that documented the inhibitory 
effect on the replication of some coronaviruses in 
epithelial lung cell cultures [25], [26], a recombinant 
HCoV-O43 coronavirus [27], and MERS-CoV [86]. 
A recently published study pointed to the extended 
inhibitory effect on several DNA and RNA viruses, 
including most human coronaviruses [19]. In addition, 
many experimental studies on coronavirus proved that 
chloroquine had a negative effect at the replication 
level [14], [19], [20]. However, one study reported 
ambiguous outcomes [87].
ACE2 is another target for chloroquine’s 
antiviral effect. ACE2 is found in the lower respiratory 
tract of humans and is a cell receptor for SARS-
CoV that is responsible for its replication and 
pathogenesis [28]. The virion glycoprotein on the 
surface of coronavirus uses the ACE2 receptor on the 
surface of human cells as a recognition site to gain 
access and facilitate both cross-species and human-to-
human transmission [29], [35]. Bronchoalveolar lavage 
fluid is used to diagnose COVID-19 when the presence 
of ACE2 is indicated in the lower respiratory tract [30]. 
In in vitro studies, chloroquine appears to interfere with 
terminal glycosylation of the cellular receptor ACE2 to 
inhibit virus-receptor binding and ultimately abrogate 
the infection [13], [31]. Chloroquine’s potent anti-
SARS-CoV effects in vitro have been documented in 
many clinical trials [15], [35], [32], [33]. ACE2 as a site 
of recognition for coronavirus raises concerns about 
its interaction with ACE inhibitors and the outcome of 
coronavirus disease. However, a recently published 
study confirmed that ACE inhibitors do not inhibit ACE2 
because ACE and ACE2 are different enzymes, and no 
data suggest that ACE inhibitor or Angiotensin II Type 1 
receptor blocker therapy facilitates coronavirus entry by 
increasing ACE2 expression in both animal and human 
subjects [34].
Chloroquine can negatively affect a pre-
entry step of the viral cycle by interfering with viral 
particles binding to their cellular cell surface receptor 
by blocking quinone reductase 2, which facilitates the 
biosynthesis of sialic acids. Sialic acids are present on 
cell transmembrane proteins as important components 
of ligand recognition [70], [71]. Interference with sialic 
acid biosynthesis might represent part of chloroquine’s 
broad antiviral spectrum against coronaviruses that 
depend on sialic acid moieties as receptors [71].
Changing the intracellular pH is chloroquine’s 
greatest potential antiviral effect because coronavirus 
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replicates in acidic environments. In fact, coronavirus cell 
entry is achieved through the endolysosomal pathway 
that depends on a certain internal pH [36]. Increasing 
endosomal pH promotes chloroquine as a potential 
powerful antiviral agent. This will affect the transduction 
of pseudotype viruses decorated with SARS-CoV 
spike protein and will affect terminal glycosylation of 
the cellular receptor ACE2 [15], [32], [33], [35]. This 
may be explained by chloroquine’s ability to diffuse 
spontaneously and rapidly across the membranes 
of cells and organelles to acidic cytoplasmic vesicles 
such as endosomes, lysosomes, or Golgi vesicles to 
alter their pH [13]. This will disturb the activity of several 
enzymes, including those essential for proteolytic 
processing and post-translational modification of viral 
proteins, which will prevent the fusion of the virus to the 
cell membrane [37], [38], [39]. Its effect may extend to 
inhibit some vital steps, such as nucleic acid replication, 
glycosylation of viral proteins, new virus particle 
transport, virus assembly, virus release to achieve its 
antiviral effects [39], and other as-yet poorly understood 
antiviral activity mechanisms [31], [39].
Chloroquine analogs prevent viral entry and 
replication processes into the cytoplasm of susceptible 
cells by neutralizing acidic pH in endosomes to abrogate 
the infections [37], [40], [41], [42], [43], [44] because low 
pH is essential for fusion of the virus and endosomal 
membranes to release the viral SARS-CoV genome 
into the cytosol [45]. In non-human coronaviruses, the 
intracellular site of coronavirus budding is influenced 
by the localization of its membrane M proteins that 
accumulate in the Golgi complex beyond the site of 
virion budding [46]. This was supported by a recent 
report that showed that the C-terminal domain of the 
MERS-CoV M protein contains a trans-Golgi network 
localization signal [47]. In addition, it affects the virus 
maturation process by impairing the proper maturation 
of the viral protein [48].
Chloroquine is an antimalarial and autoimmune 
disease medication. Its immunomodulatory effects 
encourage scientists to evaluate its performance 
on viruses. It enhances the immune response by 
promoting the export of soluble antigens into the 
cytosol of dendritic cells and directing human cytotoxic 
CD8+ T cell responses against viral antigens [49]. 
Furthermore, it organizes the cross-presentation 
of non-replicating virus antigens by dendritic cells 
to CD8+ T-cells migrated to lymph nodes at the 
site of infection and ultimately establishes a broad 
protective immune response [50]. Chloroquine inhibits 
nanoparticle endocytosis by resident macrophages; 
this effect is dose related [51], [52]. Furthermore, 
chloroquine prevents the fusion of lysosomes, which 
is likely to interfere with upstream endocytic trafficking 
by blocking the effective transport between cellular 
organelles and the cell membrane [53]. However, 
one study reported no potential effect of chloroquine 
on primary human monocyte-derived macrophages 
and dendritic cells in MERS-CoV infection [53]. 
Chloroquine is a well-known immunomodulatory drug 
that can mediate an anti-inflammatory response [37]. 
This effect has been observed in the treatment of 
viral infections and associated pathologies [13], [16]. 
Consequently, chloroquine analogs block the release of 
several cytokines, chemokines, or mediators that are 
blamed for the severity of viral infections. Therefore, 
inhibition of endosomal acidification by chloroquine 
therapy may be promoted as a potential therapeutic 
target for viral infections and associated pathologies. 
Cytokines, chemokines, and the activities of several 
host endosomal proteases depend on endosomal-
lysosomal acidification [54], [55].
One of the cytokines strongly implicated in viral 
pathologies is tumor necrosis factor-a (TNF-α), which 
activates macrophages to potentiate the production 
of mediators that facilitate both the permeability and 
infectivity of endothelial cells [56], [57]. Chloroquine’s 
key effect is its prevention of macrophage activation 
and inhibition of TNF-a secretion from various cells at 
clinically relevant concentrations [13], [37], [58] inhibition 
of TNFα mRNA expression [59], [60], [61] and reduction 
of interleukin (IL-1 and IL-6) cytokines that are released 
from monocytes and macrophages [62]. Chloroquine 
also adopts another pathway to inhibit TNFα production 
by disrupting cellular iron metabolism [63]. Moreover, 
it blocks the conversion of pro-TNF into soluble 
mature TNFα molecules, which modifies the immune 
response [64]. Chloroquine analogs enhance immune 
activation in viral infection and reduce systemic T 
cell activation [65], [66]. Chloroquine inhibits IL-1β 
mRNA expression in T helper-1 (THP-1) cells and 
reduces IL-1β production [58]. Likewise, it affects the 
immune system through cell signaling and regulation of 
proinflammatory cytokines by inhibiting phosphorylation 
of p38 mitogen-activated protein kinase in THP-1 cells 
and caspase-1 [59]. Viruses frequently require the 
phosphorylation step to replicate [26], [67].
Chloroquine blocks toll-like receptor-mediated 
activation of plasmacytoid dendritic cells and myeloid 
differentiation primary response gene 88 signaling 
through three pathways. First, it decreases the levels 
of the downstream signaling molecules IL-1 receptor-
associated kinase 4 and IFN regulatory factor 7. 
Second, it inhibits IFN-a synthesis and blocks the 
negative modulators of T-cells such as indoleamine 
2,3-dioxygenase. Third, it promotes downstream 
signaling of programmed death-ligand 1 [68]. Clinically, 
both hydroxychloroquine and chloroquine have 
immunomodulatory effects that impair the increase in 
immune factors that cause a cytokine storm, which is 
followed by multiorgan failure and potentially death. 
Therefore, early treatment with chloroquine can abort 
or modify these serious complications [41], [69].
Many clinical trials have assessed the 
therapeutic efficacy of chloroquine against coronavirus. 
In an in vitro study, chloroquine had broad-spectrum 
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antiviral effects in the control arm of SARS-CoV-2 
infection [16]. Likewise, in a mouse model, it maintained 
a higher efficacy against coronavirus [15], [72]. 
Interestingly, chloroquine showed potent inhibitory 
effects on the treated primate cells before and after 
exposure to the virus, which shows both prophylactic 
and therapeutic advantages [31]. At present, many 
clinical trials are testing chloroquine as anti-COVID-19 
therapy [73]. Chloroquine was recently promoted 
as a potential possible option for treating patients 
diagnosed with novel coronavirus pneumonia with a 
successful treatment rate, shortened hospital stay, and 
improved patient outcome. The recommended dose of 
chloroquine phosphate tablets was 500 mg twice per 
day for 10 days for mild, moderate, and severe cases 
of novel coronavirus pneumonia, providing that patients 
had no contraindications [74]. Preliminary reports 
from China suggest that approximately 100 infected 
patients treated with chloroquine experienced a more 
rapid symptomatic and radiological lung computed 
tomography improvement in addition to a shortened 
hospital stay and recovery period compared with 
control groups [1], [74], [75], [76]. This would reflect 
the first successful story for the use of chloroquine in 
humans to treat an acute viral disease and supports 
research into its potential as a therapy option during 
the current COVI-19 outbreak [77]. Based on this 
promising result, chloroquine has been included in the 
list of trial drugs in the guidelines for the diagnosis and 
treatment of COVID-19 released by the National Health 
Commission of the People’s Republic of China[74], [76]. 
In addition, the Dutch Centre of Disease Control and 
the Italian Society of Infectious and Tropical Disease 
(Lombardy section) recommend chloroquine for 
patients with COVID-19 [5], [20]. In light of the urgency, 
the absence of a vaccine and effective medications 
and the pressure health-care systems face to save 
lives during the COVID-19 pandemic, many countries, 
including the United States and France, have suggested 
using chloroquine to manage patients with COVID-19 
under certain circumstances [77], [78], [79], [80]. In 
a small sample size study that recruited 36 subjects, 
hydroxychloroquine therapy was significantly associated 
with a reduction in viral load and viral shedding period 
and worked synergistically with azithromycin against 
COVID-19 [81]. Likewise, another study, evaluating 
80 cases with a mild presentation, demonstrated 
rapid clearance of the virus and shortened the mean 
hospital stay to 5 days with combination therapy of 
hydroxychloroquine and azithromycin: Progressively 
negative results of nasopharyngeal PCR assay for 
the virus were documented at day 7 (83%) and day 
8 (93%). In addition, 97.5% of virus cultures from 
patient respiratory samples were negative on day 
5 [77]. Similarly, chloroquine prevented exacerbation 
of pneumonia with radiological improvement and 
shortened the course of the disease [1]. Interestingly, in 
an in vitro study on SARS-CoV-2, a similar synergistic 
effect was obtained in combination therapy of 
hydroxychloroquine and azithromycin, as both reduce 
the acidity of the lysosome to impair viral replication [83]. 
Chloroquine efficacy may support the observational 
thought that COVID-19 infections are highly pandemic 
in countries where malaria is the least pandemic and are 
the least pandemic in nations where malaria is highly 
pandemic [10]. On the other hand, hydroxychloroquine 
therapy for patients with COVID-19 infection was 
associated with a high risk of QT prolongation, and 
greater changes in QT were observed with concurrent 
treatment with azithromycin [84], [85] and drug-induced 
torsades de pointes [85]. Hydroxychloroquine should 
be avoided in patients with glucose-6-phosphate 
dehydrogenase deficiency to prevent hemolytic anemia. 
Both hydroxychloroquine and chloroquine have narrow 
therapeutic indices for chloroquine and are associated 
with gastrointestinal symptoms, retinopathy, deafness/
tinnitus, and life-threatening toxicity (cardiomyopathy, 
arrhythmias, and methemoglobinemia) [88]. Recently 
published data, pointed to increase frequency of 
ventricular arrhythmias associated with chloroquine 
therapy for COVID -19infection [89]. Hence, vigilance 
and cardiac monitoring are recommended to balance 
the risks and benefits.
Limitations of the study
This study was conducted by one researcher 
and used only PubMed, Scopus, and Google Scholar 
databases and timeframes, and some valuable data 
were not included. Another limitation is related to the 
article selection criteria that were used.
Conclusion
Chloroquine has a broad-spectrum range of 
documented antiviral activities and immunomodulators, 
which is supported by recent limited fruitful clinical trials 
in humans. In addition, it has a long history of use, 
anti-inflammatory advantages, safety in reasonable 
dosages, and low price. Its antiviral effects should be 
further assessed in large clinical trials in the near future.
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